Transgene : A dense clinical calendar in the coming weeks
>Financial visibility out to Q4 2025 confirmed - Transgène yesterday evening reported its H1 2024 results which contained no major surprises. Operating income totalled € 3.4m (vs € 4.8m in H1 2023). R&D costs were stable at € 15.4m and the net loss was € 16.5m (vs -€ 15.9m in H1 2023).Transgene's cash position reached € 15.3m, resulting in as expected financial visibility out to Q4 2025. This financial visibility is made possible by the fact that Transgene has al...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.